Tissium Secures €60M to Introduce Sutureless Nerve Repair System in US Operating Rooms
Tissium has raised €60M to carry the world’s only FDA-cleared sutureless nerve repair system into US operating rooms. The Paris medtech wants to swap the surgeon’s needle for a dab of light-cured glue. For a severed nerve, the standard repair has barely changed in decades. Since its founding, Tissium has been at the forefront of medical innovation, and its latest €60M funding round is a testament to its groundbreaking approach. The company's sutureless nerve glue, now FDA-cleared, promises to revolutionize nerve repair procedures, offering a more efficient and potentially less invasive option for US surgeons. This advancement could significantly reduce surgery times and improve patient outcomes, particularly in complex nerve repairs. With the funding, Tissium aims to expand its market reach and solidify its position as a leader in the medtech space. The company's unique solution challenges traditional needle-and-thread methods, suggesting a future where precise, light-cured glue replaces sutures, marking a new era in minimally invasive surgery. Read the full story A surgeon stitches the two frayed ends together under a [...]
This story continues at The Next Web